Kyowa Hakko Kirin, sanofi-aventis deal

sanofi-aventis received a non-exclusive license from Kyowa's BioWa Inc. subsidiary to use Potelligent technology to research, develop and commercialize antibodies against undisclosed targets. Potelli...